02 03 Inside HSCA: Rooney: New Survey Shows Hospitals Oppose Genentech Specialty Drug Distribution Change 04 05 15 16 19 20 21 22 23 24 25 26 27 28 31 32 33

Rooney: New Survey Shows Hospitals Oppose Genentech Specialty Drug Distribution Change

34
In a recent piece for The Journal of Healthcare Contracting, Healthcare Supply Chain Association (HSCA) President Curtis Rooney details the findings of a new survey of hospitals and academic medical centers on the impact of changes to the distribution channels for specialty cancer therapies from the biotechnology company Genentech. The survey, commissioned by HSCA member Novation, specifically found the following hospital perceptions about Genentech’s policy change:


Last fall, HSCA, the American Hospital Association (AHA) and other leading hospital advocacy groups and individual hospitals sent a letter to Genentech urging the company to continue delivering the cancer therapies through the traditional distribution channels “so that our hospitals can focus on providing the best care for their cancer patients.” 

To read the full piece in The Journal of Healthcare Contracting, click here 


35 36 37 38